{"transactions":[{"id":758841,"issuer":{"id":5181,"kind":"organization","name":"PROKIDNEY CORP."},"owners":[{"id":43192,"kind":"person","name":"Sinha Uma","position":1,"cik":"0001742587","reported_name":"Sinha Uma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director stock option (right to buy)","published_at":"2026-05-29T20:04:56.000Z","date":"2026-05-28","kind":"grant","planned":false,"acquired":true,"shares":135000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These options were granted under the Issuer's non-employee director compensation policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting."}],"balance_after":135000,"derivative":{"exercise_price":1.81,"expiration_date":"2036-05-28","underlying":"Class A Common Stock","underlying_shares":135000},"source":{"system":"sec-edgar","filing":"0001193125-26-248226","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1850270/000119312526248226/ownership.xml","form_type":"4"}},{"id":1127796,"issuer":{"id":5181,"kind":"organization","name":"PROKIDNEY CORP."},"owners":[{"id":43192,"kind":"person","name":"Sinha Uma","position":1,"cik":"0001742587","reported_name":"Sinha Uma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director stock option (right to buy)","published_at":"2025-06-02T20:14:48.000Z","date":"2025-05-29","kind":"grant","planned":false,"acquired":true,"shares":125862,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These options were granted under the Issuer's non-employee director compensation policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting."}],"balance_after":125862,"derivative":{"exercise_price":0.72,"expiration_date":"2035-05-29","underlying":"Class A Ordinary Shares","underlying_shares":125862},"source":{"system":"sec-edgar","filing":"0000950170-25-080272","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1850270/000095017025080272/ownership.xml","form_type":"4"}},{"id":1495283,"issuer":{"id":5181,"kind":"organization","name":"PROKIDNEY CORP."},"owners":[{"id":43192,"kind":"person","name":"Sinha Uma","position":1,"cik":"0001742587","reported_name":"Sinha Uma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director stock option (right to buy)","published_at":"2024-06-03T20:34:09.000Z","date":"2024-05-30","kind":"grant","planned":false,"acquired":true,"shares":62558,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These options were granted under the Issuer's non-employee director compensation policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting."}],"balance_after":62558,"derivative":{"exercise_price":4.2,"expiration_date":"2034-05-30","underlying":"Class A Ordinary Shares","underlying_shares":62558},"source":{"system":"sec-edgar","filing":"0000950170-24-068047","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1850270/000095017024068047/ownership.xml","form_type":"4"}},{"id":1839821,"issuer":{"id":5181,"kind":"organization","name":"PROKIDNEY CORP."},"owners":[{"id":43192,"kind":"person","name":"Sinha Uma","position":1,"cik":"0001742587","reported_name":"Sinha Uma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director stock option (right to buy)","published_at":"2023-07-03T13:18:45.000Z","date":"2023-06-29","kind":"grant","planned":false,"acquired":true,"shares":48128,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These options were granted under the Issuer's non-employee director compensation policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting."}],"balance_after":48128,"derivative":{"exercise_price":10.56,"expiration_date":"2033-06-29","underlying":"Class A Ordinary Shares","underlying_shares":48128},"source":{"system":"sec-edgar","filing":"0001209191-23-040425","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1850270/000120919123040425/doc4.xml","form_type":"4"}},{"id":2208100,"issuer":{"id":5181,"kind":"organization","name":"PROKIDNEY CORP."},"owners":[{"id":43192,"kind":"person","name":"Sinha Uma","position":1,"cik":"0001742587","reported_name":"Sinha Uma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2022-07-14T01:28:07.000Z","date":"2022-07-11","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a grant of 30,000 restricted stock units that vested in full on July 11, 2022 and will settle in Class A Ordinary Shares on a date selected by the issuer between the vesting date and March 15, 2023."}],"balance_after":30000,"source":{"system":"sec-edgar","filing":"0000950103-22-012368","document":"dp177039_4-sinha.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1850270/000095010322012368/dp177039_4-sinha.xml","form_type":"4"}},{"id":2892227,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":43192,"kind":"person","name":"Sinha Uma","position":1,"cik":"0001742587","reported_name":"Sinha Uma","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-01-29T00:00:37.000Z","date":"2021-01-26","kind":"disposition_to_issuer","acquired":false,"shares":60000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The option vests over four years after November 5, 2018.  At the Effective Time, each such option was cancelled, assumed by Parent and replaced with an option to purchase 1.85 shares of Parent common stock at an exercise price per share of Parent common stock equal to the exercise price per share of the Issuer option divided by 1.85.  Such Parent stock option is subject to the same terms and conditions applicable to the Issuer option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests over four years after November 5, 2018.  At the Effective Time, each such option was cancelled, assumed by Parent and replaced with an option to purchase 1.85 shares of Parent common stock at an exercise price per share of Parent common stock equal to the exercise price per share of the Issuer option divided by 1.85.  Such Parent stock option is subject to the same terms and conditions applicable to the Issuer option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":13.2,"expiration_date":"2028-11-05","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0000899243-21-003639","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1742587/000089924321003639/doc4.xml","form_type":"4"}},{"id":2892226,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":43192,"kind":"person","name":"Sinha Uma","position":1,"cik":"0001742587","reported_name":"Sinha Uma","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-01-29T00:00:37.000Z","date":"2021-01-26","kind":"other","acquired":false,"shares":303525,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger dated October 5, 2020 (the \"Merger Agreement\"), by and among the Issuer, BridgeBio Pharma, Inc. (\"Parent\"), Globe Merger Sub 1, Inc., an indirect wholly owned subsidiary of Parent (\"Merger Sub\"), and Globe Merger Sub II, Inc., an indirect wholly owned subsidiary of Parent (\"Merger Sub II\"), Merger Sub was merged with and into the Issuer, with the Issuer continuing as the surviving corporation and immediately thereafter, the Issuer was merged with and into Merger Sub II, with Merger Sub II continuing as the surviving corporation, effective as of January 26, 2021 (the \"Effective Time\"). At the Effective Time, each shares of Issuer common stock that was outstanding and held by the Reporting Person immediately prior to the Effective Time was cancelled and automatically converted into 1.85 shares of Parent common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger dated October 5, 2020 (the \"Merger Agreement\"), by and among the Issuer, BridgeBio Pharma, Inc. (\"Parent\"), Globe Merger Sub 1, Inc., an indirect wholly owned subsidiary of Parent (\"Merger Sub\"), and Globe Merger Sub II, Inc., an indirect wholly owned subsidiary of Parent (\"Merger Sub II\"), Merger Sub was merged with and into the Issuer, with the Issuer continuing as the surviving corporation and immediately thereafter, the Issuer was merged with and into Merger Sub II, with Merger Sub II continuing as the surviving corporation, effective as of January 26, 2021 (the \"Effective Time\"). At the Effective Time, each shares of Issuer common stock that was outstanding and held by the Reporting Person immediately prior to the Effective Time was cancelled and automatically converted into 1.85 shares of Parent common stock."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-21-003639","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1742587/000089924321003639/doc4.xml","form_type":"4"}},{"id":2892225,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":43192,"kind":"person","name":"Sinha Uma","position":1,"cik":"0001742587","reported_name":"Sinha Uma","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-01-29T00:00:37.000Z","date":"2020-10-27","kind":"gift","acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":303525,"source":{"system":"sec-edgar","filing":"0000899243-21-003639","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1742587/000089924321003639/doc4.xml","form_type":"4"}},{"id":2906163,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":43192,"kind":"person","name":"Sinha Uma","position":1,"cik":"0001742587","reported_name":"Sinha Uma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-01-15T21:05:08.000Z","date":"2021-01-13","kind":"sale","acquired":false,"shares":300,"price":126.39,"value":37917.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on August 13, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Represents the weighted average sale price of the shares sold ranging from $126.30 to $126.57 per share."}],"balance_after":306525,"source":{"system":"sec-edgar","filing":"0000899243-21-002179","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1742587/000089924321002179/doc4.xml","form_type":"4"}},{"id":2906162,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":43192,"kind":"person","name":"Sinha Uma","position":1,"cik":"0001742587","reported_name":"Sinha Uma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-01-15T21:05:08.000Z","date":"2021-01-13","kind":"sale","acquired":false,"shares":2000,"price":125.35,"value":250700.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on August 13, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents the weighted average sale price of the shares sold ranging from $125.11 to $125.66 per share."}],"balance_after":306825,"source":{"system":"sec-edgar","filing":"0000899243-21-002179","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1742587/000089924321002179/doc4.xml","form_type":"4"}},{"id":2906161,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":43192,"kind":"person","name":"Sinha Uma","position":1,"cik":"0001742587","reported_name":"Sinha Uma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-01-15T21:05:08.000Z","date":"2021-01-13","kind":"sale","acquired":false,"shares":4934,"price":124.7187,"value":615362.0658,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on August 13, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents the weighted average sale price of the shares sold ranging from $124.10 to $125.09 per share."}],"balance_after":308825,"source":{"system":"sec-edgar","filing":"0000899243-21-002179","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1742587/000089924321002179/doc4.xml","form_type":"4"}},{"id":2906160,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":43192,"kind":"person","name":"Sinha Uma","position":1,"cik":"0001742587","reported_name":"Sinha Uma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-01-15T21:05:08.000Z","date":"2021-01-13","kind":"sale","acquired":false,"shares":1498,"price":123.4787,"value":184971.0926,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on August 13, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average sale price of the shares sold ranging from $123.01 to $124.00 per share."}],"balance_after":313759,"source":{"system":"sec-edgar","filing":"0000899243-21-002179","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1742587/000089924321002179/doc4.xml","form_type":"4"}},{"id":2906159,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":43192,"kind":"person","name":"Sinha Uma","position":1,"cik":"0001742587","reported_name":"Sinha Uma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-01-15T21:05:08.000Z","date":"2021-01-13","kind":"sale","acquired":false,"shares":572,"price":122.2667,"value":69936.5524,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on August 13, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price of the shares sold ranging from $121.98 to $122.89 per share."}],"balance_after":315257,"source":{"system":"sec-edgar","filing":"0000899243-21-002179","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1742587/000089924321002179/doc4.xml","form_type":"4"}},{"id":2906158,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":43192,"kind":"person","name":"Sinha Uma","position":1,"cik":"0001742587","reported_name":"Sinha Uma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-01-15T21:05:08.000Z","date":"2021-01-13","kind":"sale","acquired":false,"shares":696,"price":121.1094,"value":84292.1424,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on August 13, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the shares sold ranging from $120.81 to $121.33 per share.  The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 through 7."}],"balance_after":315829,"source":{"system":"sec-edgar","filing":"0000899243-21-002179","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1742587/000089924321002179/doc4.xml","form_type":"4"}},{"id":2940363,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":43192,"kind":"person","name":"Sinha Uma","position":1,"cik":"0001742587","reported_name":"Sinha Uma","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-12-17T21:05:16.000Z","date":"2020-12-15","kind":"grant","acquired":true,"shares":5717,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option was acquired in connection with an equity exchange program involving the issuance of equity awards under the Issuer's 2019 Stock Option and Incentive Plan in exchange for existing equity held by the Reporting Person in a privately-held subsidiary of the Issuer.  The number of option shares and per share exercise price of the new option was determined based on the number of shares and per share exercise price of the subsidiary option at a certain exchange ratio."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"2,144 shares subject to the stock option were vested as of the date of acquisition, 119 shares shall vest on January 1, 2021, and 3,454 shares shall vest in monthly installments over the next 29 months thereafter, in each case so long as the Reporting Person continues to have a service relationship with the Issuer or a Subsidiary on each such date."}],"balance_after":5717,"derivative":{"exercise_price":42.8,"expiration_date":"2030-09-29","underlying":"Common Stock","underlying_shares":5717},"source":{"system":"sec-edgar","filing":"0000899243-20-034284","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320034284/doc4.xml","form_type":"4"}},{"id":2940362,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":43192,"kind":"person","name":"Sinha Uma","position":1,"cik":"0001742587","reported_name":"Sinha Uma","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-12-17T21:05:16.000Z","date":"2020-12-15","kind":"grant","acquired":true,"shares":10832,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option was acquired in connection with an equity exchange program involving the issuance of equity awards under the Issuer's 2019 Stock Option and Incentive Plan in exchange for existing equity held by the Reporting Person in a privately-held subsidiary of the Issuer.  The number of option shares and per share exercise price of the new option was determined based on the number of shares and per share exercise price of the subsidiary option at a certain exchange ratio."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"4,062 shares subject to the stock option were vested as of the date of acquisition, 226 shares shall vest on January 1, 2021, and 6,544 shares shall vest in monthly installments over the next 29 months thereafter, in each case so long as the Reporting Person continues to have a service relationship with the Issuer or a Subsidiary on each such date."}],"balance_after":10832,"derivative":{"exercise_price":3.07,"expiration_date":"2030-07-20","underlying":"Common Stock","underlying_shares":10832},"source":{"system":"sec-edgar","filing":"0000899243-20-034284","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320034284/doc4.xml","form_type":"4"}},{"id":2940361,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":43192,"kind":"person","name":"Sinha Uma","position":1,"cik":"0001742587","reported_name":"Sinha Uma","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-12-17T21:05:16.000Z","date":"2020-12-15","kind":"grant","acquired":true,"shares":8912,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option was acquired in connection with an equity exchange program involving the issuance of equity awards under the Issuer's 2019 Stock Option and Incentive Plan in exchange for existing equity held by the Reporting Person in a privately-held subsidiary of the Issuer.  The number of option shares and per share exercise price of the new option was determined based on the number of shares and per share exercise price of the subsidiary option at a certain exchange ratio."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"3,342 shares subject to the stock option were vested as of the date of acquisition, 186 shares shall vest on January 1, 2021, and 5,384 shares shall vest in monthly installments over the next 29 months thereafter, in each case so long as the Reporting Person continues to have a service relationship with the Issuer or a Subsidiary on each such date."}],"balance_after":8912,"derivative":{"exercise_price":3.07,"expiration_date":"2030-04-01","underlying":"Common Stock","underlying_shares":8912},"source":{"system":"sec-edgar","filing":"0000899243-20-034284","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320034284/doc4.xml","form_type":"4"}},{"id":2956686,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":43192,"kind":"person","name":"Sinha Uma","position":1,"cik":"0001742587","reported_name":"Sinha Uma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2020-12-04T22:34:40.000Z","date":"2020-12-02","kind":"sale","acquired":false,"shares":200,"price":92.965,"value":18593.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on August 13, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents the weighted average sale price of the shares sold ranging from $92.71 to $93.22 per share."}],"balance_after":316525,"source":{"system":"sec-edgar","filing":"0000899243-20-032771","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1742587/000089924320032771/doc4.xml","form_type":"4"}},{"id":2956685,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":43192,"kind":"person","name":"Sinha Uma","position":1,"cik":"0001742587","reported_name":"Sinha Uma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2020-12-04T22:34:40.000Z","date":"2020-12-02","kind":"sale","acquired":false,"shares":300,"price":91.89,"value":27567.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on August 13, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average sale price of the shares sold ranging from $91.56 to $92.10 per share."}],"balance_after":316725,"source":{"system":"sec-edgar","filing":"0000899243-20-032771","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1742587/000089924320032771/doc4.xml","form_type":"4"}},{"id":2956684,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":43192,"kind":"person","name":"Sinha Uma","position":1,"cik":"0001742587","reported_name":"Sinha Uma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2020-12-04T22:34:40.000Z","date":"2020-12-02","kind":"sale","acquired":false,"shares":702,"price":90.6339,"value":63624.9978,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on August 13, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price of the shares sold ranging from $90.33 to $91.18 per share."}],"balance_after":317025,"source":{"system":"sec-edgar","filing":"0000899243-20-032771","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1742587/000089924320032771/doc4.xml","form_type":"4"}},{"id":2956683,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":43192,"kind":"person","name":"Sinha Uma","position":1,"cik":"0001742587","reported_name":"Sinha Uma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2020-12-04T22:34:40.000Z","date":"2020-12-02","kind":"sale","acquired":false,"shares":3798,"price":89.6267,"value":340402.2066,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on August 13, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the shares sold ranging from $89.15 to $90.125 per share.  The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 through 5."}],"balance_after":317727,"source":{"system":"sec-edgar","filing":"0000899243-20-032771","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1742587/000089924320032771/doc4.xml","form_type":"4"}},{"id":2975444,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":43192,"kind":"person","name":"Sinha Uma","position":1,"cik":"0001742587","reported_name":"Sinha Uma","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2020-11-19T00:39:39.000Z","date":"2020-11-16","kind":"exercise","acquired":false,"shares":469,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs vest over approximately four years with a vesting commencement date of May 16, 2020 and have no expiration date.  6.25% of the RSUs vested on August 16, 2020 and November 16, 2020 and an additional 6.25% will vest in quarterly installments on the 16th day of each February, May, August and November thereafter, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs vest over approximately four years with a vesting commencement date of May 16, 2020 and have no expiration date.  6.25% of the RSUs vested on August 16, 2020 and November 16, 2020 and an additional 6.25% will vest in quarterly installments on the 16th day of each February, May, August and November thereafter, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date."}],"balance_after":6563,"derivative":{"underlying":"Common Stock","underlying_shares":469},"source":{"system":"sec-edgar","filing":"0000899243-20-031549","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320031549/doc4.xml","form_type":"4"}},{"id":2975443,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":43192,"kind":"person","name":"Sinha Uma","position":1,"cik":"0001742587","reported_name":"Sinha Uma","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2020-11-19T00:39:39.000Z","date":"2020-11-16","kind":"exercise","acquired":true,"shares":469,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":16460,"source":{"system":"sec-edgar","filing":"0000899243-20-031549","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320031549/doc4.xml","form_type":"4"}},{"id":2997492,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":43192,"kind":"person","name":"Sinha Uma","position":1,"cik":"0001742587","reported_name":"Sinha Uma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2020-10-30T20:55:10.000Z","date":"2020-10-29","kind":"sale","acquired":false,"shares":3700,"price":72.6016,"value":268625.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on August 13, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price of the shares sold ranging from $72.29 to $72.94 per share."}],"balance_after":321525,"source":{"system":"sec-edgar","filing":"0000899243-20-029938","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1742587/000089924320029938/doc4.xml","form_type":"4"}},{"id":2997491,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":43192,"kind":"person","name":"Sinha Uma","position":1,"cik":"0001742587","reported_name":"Sinha Uma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2020-10-30T20:55:10.000Z","date":"2020-10-29","kind":"sale","acquired":false,"shares":1300,"price":71.9024,"value":93473.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on August 13, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the shares sold ranging from $71.26 to $72.23 per share.  The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3."}],"balance_after":325225,"source":{"system":"sec-edgar","filing":"0000899243-20-029938","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1742587/000089924320029938/doc4.xml","form_type":"4"}},{"id":3016498,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":43192,"kind":"person","name":"Sinha Uma","position":1,"cik":"0001742587","reported_name":"Sinha Uma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2020-10-02T23:43:35.000Z","date":"2020-10-01","kind":"sale","acquired":false,"shares":4831,"price":52.3542,"value":252923.1402,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on August 13, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the shares sold ranging from $52.05 to $53.00 per share.  The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":326525,"source":{"system":"sec-edgar","filing":"0000899243-20-026974","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1742587/000089924320026974/doc4.xml","form_type":"4"}},{"id":3016497,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":43192,"kind":"person","name":"Sinha Uma","position":1,"cik":"0001742587","reported_name":"Sinha Uma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2020-10-02T23:43:35.000Z","date":"2020-09-30","kind":"sale","acquired":false,"shares":100,"price":52,"value":5200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on August 13, 2020."}],"balance_after":331356,"source":{"system":"sec-edgar","filing":"0000899243-20-026974","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1742587/000089924320026974/doc4.xml","form_type":"4"}},{"id":3016496,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":43192,"kind":"person","name":"Sinha Uma","position":1,"cik":"0001742587","reported_name":"Sinha Uma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2020-10-02T23:43:35.000Z","date":"2020-09-30","kind":"sale","acquired":false,"shares":69,"price":52.08,"value":3593.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on August 13, 2020."}],"balance_after":331456,"source":{"system":"sec-edgar","filing":"0000899243-20-026974","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1742587/000089924320026974/doc4.xml","form_type":"4"}},{"id":3054524,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":43192,"kind":"person","name":"Sinha Uma","position":1,"cik":"0001742587","reported_name":"Sinha Uma","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2020-08-18T23:03:40.000Z","date":"2020-08-16","kind":"exercise","acquired":false,"shares":468,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs vest over approximately four years with a vesting commencement date of May 16, 2020 and have no expiration date.  6.25% of the RSUs vested on August 16, 2020 and an additional 6.25% will vest in quarterly installments on the 16th day of each February, May, August and November thereafter, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs vest over approximately four years with a vesting commencement date of May 16, 2020 and have no expiration date.  6.25% of the RSUs vested on August 16, 2020 and an additional 6.25% will vest in quarterly installments on the 16th day of each February, May, August and November thereafter, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date."}],"balance_after":7032,"derivative":{"underlying":"Common Stock","underlying_shares":468},"source":{"system":"sec-edgar","filing":"0000899243-20-022792","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320022792/doc4.xml","form_type":"4"}},{"id":3054523,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":43192,"kind":"person","name":"Sinha Uma","position":1,"cik":"0001742587","reported_name":"Sinha Uma","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2020-08-18T23:03:40.000Z","date":"2020-08-16","kind":"exercise","acquired":true,"shares":468,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":15991,"source":{"system":"sec-edgar","filing":"0000899243-20-022792","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320022792/doc4.xml","form_type":"4"}},{"id":3120643,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":43192,"kind":"person","name":"Sinha Uma","position":1,"cik":"0001742587","reported_name":"Sinha Uma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2020-06-05T20:05:21.000Z","date":"2020-05-31","kind":"grant","acquired":true,"shares":444,"price":41.5735,"value":18458.634,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares acquired pursuant to the Issuer's 2018 Employee Stock Purchase Plan."}],"balance_after":331525,"source":{"system":"sec-edgar","filing":"0000899243-20-015410","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1742587/000089924320015410/doc4.xml","form_type":"4"}},{"id":3124509,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":43192,"kind":"person","name":"Sinha Uma","position":1,"cik":"0001742587","reported_name":"Sinha Uma","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2020-06-03T20:07:39.000Z","date":"2020-06-01","kind":"grant","acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs will vest approximately four years with a vesting commencement date of May 16, 2020.  6.25% of the RSUs will vest on August 16, 2020 and an additional 6.25% will vest in quarterly installments thereafter, subject to continued service with the Issuer or any of its subsidiaries through each applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs will vest approximately four years with a vesting commencement date of May 16, 2020.  6.25% of the RSUs will vest on August 16, 2020 and an additional 6.25% will vest in quarterly installments thereafter, subject to continued service with the Issuer or any of its subsidiaries through each applicable vesting date."}],"balance_after":7500,"derivative":{"underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0000899243-20-015047","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320015047/doc4.xml","form_type":"4"}},{"id":3139299,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":43192,"kind":"person","name":"Sinha Uma","position":1,"cik":"0001742587","reported_name":"Sinha Uma","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-05-21T20:18:13.000Z","date":"2020-05-19","kind":"grant","acquired":true,"shares":3022,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The option was acquired in connection with an equity exchange program involving the issuance of equity awards under the Issuer's 2019 Stock Option and Incentive Plan in exchange for existing equity held by the Reporting Person in Subsidiaries of the Issuer.  The number of option shares and per share exercise price of the new option was determined based on the number of shares and per share exercise price of the subsidiary option at a certain exchange ratio."}],"balance_after":3022,"derivative":{"exercise_price":3.35,"exercise_date":"2020-05-19","expiration_date":"2029-09-30","underlying":"Common Stock","underlying_shares":3022},"source":{"system":"sec-edgar","filing":"0000899243-20-013835","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320013835/doc4.xml","form_type":"4"}},{"id":3139298,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":43192,"kind":"person","name":"Sinha Uma","position":1,"cik":"0001742587","reported_name":"Sinha Uma","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-05-21T20:18:13.000Z","date":"2020-05-19","kind":"grant","acquired":true,"shares":49765,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The option was acquired in connection with an equity exchange program involving the issuance of equity awards under the Issuer's 2019 Stock Option and Incentive Plan in exchange for existing equity held by the Reporting Person in Subsidiaries of the Issuer.  The number of option shares and per share exercise price of the new option was determined based on the number of shares and per share exercise price of the subsidiary option at a certain exchange ratio."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25,134 shares subject to the stock option were vested and exercisable as of the date of acquisition, 1,571 shares shall vest and become exercisable on June 1, 2020, and 23,060 shares shall vest and become exercisable in monthly installments over the next 15 months thereafter, in each case so long as the Reporting Person continues to have a service relationship with the Issuer or a Subsidiary on each such date."}],"balance_after":49765,"derivative":{"exercise_price":0.34,"expiration_date":"2029-07-14","underlying":"Common Stock","underlying_shares":49765},"source":{"system":"sec-edgar","filing":"0000899243-20-013835","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320013835/doc4.xml","form_type":"4"}},{"id":3139297,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":43192,"kind":"person","name":"Sinha Uma","position":1,"cik":"0001742587","reported_name":"Sinha Uma","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-05-21T20:18:13.000Z","date":"2020-05-19","kind":"grant","acquired":true,"shares":49361,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The option was acquired in connection with an equity exchange program involving the issuance of equity awards under the Issuer's 2019 Stock Option and Incentive Plan in exchange for existing equity held by the Reporting Person in Subsidiaries of the Issuer.  The number of option shares and per share exercise price of the new option was determined based on the number of shares and per share exercise price of the subsidiary option at a certain exchange ratio."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"24,930 shares subject to the stock option were vested and exercisable as of the date of acquisition, 1,558 shares shall vest and become exercisable on June 1, 2020, and 22,873 shares shall vest and become exercisable in monthly installments over the next 15 months thereafter, in each case so long as the Reporting Person continues to have a service relationship with the Issuer or a Subsidiary on each such date."}],"balance_after":49361,"derivative":{"exercise_price":0.16,"expiration_date":"2029-05-23","underlying":"Common Stock","underlying_shares":49361},"source":{"system":"sec-edgar","filing":"0000899243-20-013835","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320013835/doc4.xml","form_type":"4"}},{"id":3139296,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":43192,"kind":"person","name":"Sinha Uma","position":1,"cik":"0001742587","reported_name":"Sinha Uma","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-05-21T20:18:13.000Z","date":"2020-05-19","kind":"grant","acquired":true,"shares":5366,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The option was acquired in connection with an equity exchange program involving the issuance of equity awards under the Issuer's 2019 Stock Option and Incentive Plan in exchange for existing equity held by the Reporting Person in Subsidiaries of the Issuer.  The number of option shares and per share exercise price of the new option was determined based on the number of shares and per share exercise price of the subsidiary option at a certain exchange ratio."}],"balance_after":5366,"derivative":{"exercise_price":1.25,"exercise_date":"2020-05-19","expiration_date":"2027-11-15","underlying":"Common Stock","underlying_shares":5366},"source":{"system":"sec-edgar","filing":"0000899243-20-013835","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320013835/doc4.xml","form_type":"4"}},{"id":3139295,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":43192,"kind":"person","name":"Sinha Uma","position":1,"cik":"0001742587","reported_name":"Sinha Uma","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2020-05-21T20:18:13.000Z","date":"2020-05-19","kind":"grant","acquired":true,"shares":1523,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were acquired in connection with an equity exchange program involving the issuance of equity awards under the Issuer's 2019 Stock Option and Incentive Plan in exchange for existing equity held by the Reporting Person in privately-held subsidiaries of the Issuer (each, a \"Subsidiary\" and collectively, the \"Subsidiaries\")."}],"balance_after":15523,"source":{"system":"sec-edgar","filing":"0000899243-20-013835","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320013835/doc4.xml","form_type":"4"}},{"id":3334016,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":43192,"kind":"person","name":"Sinha Uma","position":1,"cik":"0001742587","reported_name":"Sinha Uma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2019-12-20T21:32:55.000Z","date":"2019-12-18","kind":"sale","acquired":false,"shares":1702,"price":63.3141,"value":107760.5982,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price of the shares sold from $63.10 to $63.785 per share."}],"balance_after":331081,"source":{"system":"sec-edgar","filing":"0000899243-19-029765","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1742587/000089924319029765/doc4.xml","form_type":"4"}},{"id":3334015,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":43192,"kind":"person","name":"Sinha Uma","position":1,"cik":"0001742587","reported_name":"Sinha Uma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2019-12-20T21:32:55.000Z","date":"2019-12-18","kind":"sale","acquired":false,"shares":825,"price":62.4879,"value":51552.5175,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the shares sold from $62.08 to $63.075 per share"}],"balance_after":332783,"source":{"system":"sec-edgar","filing":"0000899243-19-029765","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1742587/000089924319029765/doc4.xml","form_type":"4"}},{"id":3334014,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":43192,"kind":"person","name":"Sinha Uma","position":1,"cik":"0001742587","reported_name":"Sinha Uma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2019-12-20T21:32:55.000Z","date":"2019-12-18","kind":"sale","acquired":false,"shares":9973,"price":61.6144,"value":614480.4112,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average sale price of the shares sold from $61.085 to $62.075 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all sales reported in footnotes 1 through 3."}],"balance_after":333608,"source":{"system":"sec-edgar","filing":"0000899243-19-029765","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1742587/000089924319029765/doc4.xml","form_type":"4"}},{"id":3405237,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":43192,"kind":"person","name":"Sinha Uma","position":1,"cik":"0001742587","reported_name":"Sinha Uma","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2019-09-27T20:05:40.000Z","date":"2019-09-25","kind":"sale","acquired":false,"shares":100,"price":39.15,"value":3915.0,"ownership":{"direct":true},"balance_after":343581,"source":{"system":"sec-edgar","filing":"0000899243-19-024339","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1742587/000089924319024339/doc4.xml","form_type":"4"}},{"id":3405236,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":43192,"kind":"person","name":"Sinha Uma","position":1,"cik":"0001742587","reported_name":"Sinha Uma","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2019-09-27T20:05:40.000Z","date":"2019-09-25","kind":"sale","acquired":false,"shares":2400,"price":38.3756,"value":92101.44,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average sale price of the shares sold from $37.94 to $38.80 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":343681,"source":{"system":"sec-edgar","filing":"0000899243-19-024339","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1742587/000089924319024339/doc4.xml","form_type":"4"}},{"id":3454345,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":43192,"kind":"person","name":"Sinha Uma","position":1,"cik":"0001742587","reported_name":"Sinha Uma","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2019-07-29T20:05:56.000Z","date":"2019-07-25","kind":"sale","acquired":false,"shares":33,"price":38.35,"value":1265.55,"ownership":{"direct":true},"balance_after":346081,"source":{"system":"sec-edgar","filing":"0000899243-19-020520","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1742587/000089924319020520/doc4.xml","form_type":"4"}},{"id":3454344,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":43192,"kind":"person","name":"Sinha Uma","position":1,"cik":"0001742587","reported_name":"Sinha Uma","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2019-07-29T20:05:56.000Z","date":"2019-07-25","kind":"sale","acquired":false,"shares":700,"price":37.31,"value":26117.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average sale price of the shares sold from $37.11 to $37.45 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":346114,"source":{"system":"sec-edgar","filing":"0000899243-19-020520","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1742587/000089924319020520/doc4.xml","form_type":"4"}},{"id":3454343,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":43192,"kind":"person","name":"Sinha Uma","position":1,"cik":"0001742587","reported_name":"Sinha Uma","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2019-07-29T20:05:56.000Z","date":"2019-07-25","kind":"sale","acquired":false,"shares":1300,"price":36.5269,"value":47484.97,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price of the shares sold from $36.08 to $37.05 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":346814,"source":{"system":"sec-edgar","filing":"0000899243-19-020520","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1742587/000089924319020520/doc4.xml","form_type":"4"}},{"id":3454342,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":43192,"kind":"person","name":"Sinha Uma","position":1,"cik":"0001742587","reported_name":"Sinha Uma","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2019-07-29T20:05:56.000Z","date":"2019-07-25","kind":"sale","acquired":false,"shares":2967,"price":35.6453,"value":105759.6051,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the shares sold from $35.07 to $36.06 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":348114,"source":{"system":"sec-edgar","filing":"0000899243-19-020520","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1742587/000089924319020520/doc4.xml","form_type":"4"}},{"id":3454341,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":43192,"kind":"person","name":"Sinha Uma","position":1,"cik":"0001742587","reported_name":"Sinha Uma","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2019-07-29T20:05:56.000Z","date":"2019-05-31","kind":"grant","acquired":true,"shares":1769,"price":12.0105,"value":21246.5745,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares acquired pursuant to the Issuer's 2018 Employee Stock Purchase Plan."}],"balance_after":351081,"source":{"system":"sec-edgar","filing":"0000899243-19-020520","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1742587/000089924319020520/doc4.xml","form_type":"4"}},{"id":3468289,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":43192,"kind":"person","name":"Sinha Uma","position":1,"cik":"0001742587","reported_name":"Sinha Uma","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2019-07-03T20:17:11.000Z","date":"2019-07-01","kind":"purchase","acquired":true,"shares":14000,"price":17,"value":238000.0,"ownership":{"direct":true},"balance_after":14000,"source":{"system":"sec-edgar","filing":"0000899243-19-019150","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924319019150/doc4.xml","form_type":"4"}},{"id":3510409,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":43192,"kind":"person","name":"Sinha Uma","position":1,"cik":"0001742587","reported_name":"Sinha Uma","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2019-05-28T20:01:29.000Z","date":"2019-05-23","kind":"sale","acquired":false,"shares":800,"price":27.88,"value":22304.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price of the shares sold ranging from $27.55 to $28.43 per share.  The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":349312,"source":{"system":"sec-edgar","filing":"0000899243-19-014838","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1742587/000089924319014838/doc4.xml","form_type":"4"}},{"id":3510408,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":43192,"kind":"person","name":"Sinha Uma","position":1,"cik":"0001742587","reported_name":"Sinha Uma","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2019-05-28T20:01:29.000Z","date":"2019-05-23","kind":"sale","acquired":false,"shares":4200,"price":27.16,"value":114072.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the shares sold ranging from $26.52 to $27.51 per share.  The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":350112,"source":{"system":"sec-edgar","filing":"0000899243-19-014838","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1742587/000089924319014838/doc4.xml","form_type":"4"}},{"id":3510407,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":43192,"kind":"person","name":"Sinha Uma","position":1,"cik":"0001742587","reported_name":"Sinha Uma","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2019-05-28T20:01:29.000Z","date":"2018-11-30","kind":"grant","acquired":true,"shares":1081,"price":12.01,"value":12982.81,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares acquired pursuant to the Issuer's 2018 Employee Stock Purchase Plan."}],"balance_after":354312,"source":{"system":"sec-edgar","filing":"0000899243-19-014838","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1742587/000089924319014838/doc4.xml","form_type":"4"}},{"id":3771608,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":43192,"kind":"person","name":"Sinha Uma","position":1,"cik":"0001742587","reported_name":"Sinha Uma","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2018-11-08T00:06:17.000Z","date":"2018-11-05","kind":"grant","acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Reporting Person is a participant in the Issuer's 2018 Stock Option and Incentive Plan and received 60,000 stock options (the \"Grant\") on November 5, 2018.  The shares subject to the Grant shall vest as follows: one quarter of the shares shall vest on November 5, 2019 and the remaining unvested shares shall vest ratably over the following 36 months, subject to the Reporting Person's continued service to the Issuer through each vesting date."}],"balance_after":60000,"derivative":{"exercise_price":13.2,"expiration_date":"2028-11-05","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0000899243-18-028483","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1742587/000089924318028483/doc4.xml","form_type":"4"}}]}